Page 4 - Initial Statements News Today

Commits to Capital Return of Up to $3.15 per Share Adds Three New Directors and Forms Capital Allocation Committee of the Board ...

Files Definitive Consent Revocation Statement Mails Letter to Stockholders Highlighting the Path to Realizing the Full Value of Their MEI Investment Urges Stockholders Not to be Misled by Anson...

Bristol Myers Squibb to Acquire Mirati Therapeutics Transaction Terms and Financial Details ...

Bristol Myers Squibb to Acquire Mirati for $58.00 Per Share, Representing $4.8 Billion Equity Value and Up to $5.8 Billion Including the Contingent Value Right Acquisition Brings KRAZATI® (adagrasib), a Best-in-Class KRASG12C Inhibitor Approved by the U.S. FDA for the Treatment of Patients with Advanced Non-Small Ce...

Bristol Myers Squibb Strengthens & Diversifies Oncology Portfolio with Acquisition of Mirati Therapeutics October 8, 2023 Not for Product...

Bristol Myers Squibb to Acquire Mirati for $58.00 Per Share, Representing $4.8 Billion Equity Value and Up to $5.8 Billion Including the Contingent Value Right Acquisition Brings KRAZATI® , a...

MEI Pharma, Inc. , a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that its Board of Directors has unanimously approved the adoption of a limited-duration stockholder rights plan ("Rights Plan")...

MEI Pharma, Inc. today issued the following statement in response to the consent solicitation initiated by a group led by Anson Advisors Inc. and Cable Car Capital LLC. The MEI Board of Directors...

No Stockholder Action Required at This Time ...

Second Quarter Highlights Include: Revenue for the second quarter of 2023 was $192.2 million, compared to $156.6 million for the same quarter of 2022, an increase of 22.7%. Environmental...